Verastem Oncology Doses First Participant In Its TARGET-D-201 Phase 2 Registration-Directed Study Of VS-7375 To KRAS G12D-Mutated Metastatic Pancreatic Ductal Carcinoma

뉴스 본문을 불러오고 있어요.

Verastem Oncology Doses First Participant In Its TARGET-D-201 Phase 2 Registration-Directed Study Of VS-7375 To KRAS G12D-Mutated Metastatic Pancreatic Ductal Carcinoma | 웨이프 WAPE

Verastem Oncology Doses First Participant In Its TARGET-D-201 Phase 2 Registration-Directed Study Of VS-7375 To KRAS G12D-Mutated Metastatic Pancreatic Ductal Carcinoma

기사 요약

관련 종목

댓글 —